Executive Summary
Diffuse coronary physiologic burden — not focal stenosis — predicts death and heart failure after TAVI, per a 164-patient retrospective analysis in Catheterization and Cardiovascular Interventions showing each 0.1 drop in mean angiography-derived FFR carried an adjusted HR of 1.62 for the composite endpoint despite no epicardial stenosis ≥70%. The lowest single-vessel vFFR did nothing; the patient-level mean did the work. That reframes how the Heart Team should read pre-TAVI angiograms and complicates the "clean coronaries, proceed to valve" reflex. A parallel Navitor real-world series (N=218) confirmed intra-annular self-expanding hemodynamics hold up in small annuli, and a 340-patient AMYLOCOR validation found the RAISE score for ATTR-CA in AS delivered only moderate discrimination (AUC 0.69). Sparse day; the physiologic-burden signal is the story.
- Mean vFFR ≤0.85 stratified 26% of TAVI patients into a higher-risk cohort with no obstructive CAD on angiography (CCI).
- Navitor TAVI in small annuli (≤430 mm²) yielded a 12-month clinical composite of 8.8% vs 10.2% in larger annuli, with mean gradients ≥20 mmHg at 1.1% (CCI).
- ATTR-CA prevalence in a Spanish TAVR referral cohort was 4.1%, lower than prior reports; RAISE ≥2 flagged only 7.2% positivity (Int J Cardiol).
- End-to-end 3D DenseNet on pre-TAVI whole-body CT hit AUC 0.787 for <12-month mortality without feature engineering (Stud Health Technol Inform).
- CT-derived indexed extracellular volume dropped 15% at 6 months post-TAVI; worsening was tied to residual aortic regurgitation (CCI).
What to watch: Edwards Q3 earnings on October 29 will set the tone for TAVR volume trajectory heading into the 2025 ESC guideline implementation cycle.
Aortic Valve (TAVR/TAVI)
The day's aortic signal is a rebuke to lesion-based thinking. The CCI vFFR analysis (retrospective, single-center, N=164, mean follow-up 1241 days) showed patient-level mean vFFR — not the worst single vessel — independently predicted death or HF hospitalization (adjusted HR 1.62 per 0.1 decrement, P=0.035). All patients had <70% angiographic stenosis. Hypothesis-generating at this sample size, but the finding aligns with the established pathophysiology: diffuse microvascular and epicardial dysfunction in the pressure-overloaded LV is not captured by percent-diameter cutoff. Neither ACC/AHA 2020 nor ESC 2025 recommends physiologic assessment in non-obstructive pre-TAVI angiography; both guidelines default to lesion-based revascularization decisions. [NOTABLE] if replicated prospectively.
The Navitor small-annulus data (N=218, 41.7% small annulus, non-randomized) matters because small annuli have historically been the intra-annular valve's Achilles heel. Mean gradients ran 7.7 vs 6.6 mmHg with equivalent 12-month clinical composites (8.8% vs 10.2%). ESC 2025 favors SAVR with root enlargement in patients <70 with small annuli where PPM risk is high — a comparator this single-arm registry does not address. Separately, an Osaka ECV study (N=55) found post-TAVI myocardial remodeling reverses in most patients, but 16.4% show worsening indexed ECV tied to residual AR — another argument for aggressive AR management at implant.
Case-level reminders: coronary obstruction from mitral calcified amorphous tumor embolization during Evolut FX deployment (JACC Case Reports), subacute HALT despite DOAC therapy, and a descending thoracic pseudoaneurysm after aborted transfemoral TAVI salvaged with staged TEVAR plus transapical valve-in-valve.
Mitral Valve (MitraClip, PASCAL, TMVR)
A JACC Case Reports description of ECMO-supported valve-in-valve TMVR using balloon-assisted anterior mitral leaflet translocation (BATMAN-style) illustrates how far high-risk TMVR has pushed to solve neo-LVOT obstruction — the field's persistent anatomic barrier. A 74-year-old with a degenerated 27-mm surgical bioprosthesis received a 26-mm balloon-expandable valve using an LV pacing guidewire and 13-F steerable sheath. Single case. ESC 2025 rates TMVI Class IIb for degenerative MS with MAC at experienced centres, explicitly acknowledging the high-risk nature of all interventions in this population; redo surgical MVR remains the reference standard when operability exists. No trial-level mitral data today.
Tricuspid Valve (TriClip, TTVR)
No tricuspid-specific studies in today's feed. The ESC 2025 now rates transcatheter TV treatment Class IIa for high-risk symptomatic severe TR — based on TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II — while ACC/AHA 2020 contains no transcatheter TR recommendation at all, a gap that grows more conspicuous with each new real-world dataset. Recent STS/ACC TVT Registry data on EVOQUE TTVR showed 98.4% implant success, 3.1% 30-day mortality, and a new CIED implantation rate of 15.9% in CIED-naive patients — lower than observed in the TRISCEND II pivotal trial, a signal that real-world operator selection may be outpacing the durability data.
Surgical vs. Transcatheter Comparisons
No head-to-head trials today. The vFFR finding does something the SAVR-vs-TAVR literature rarely does: it identifies a physiologic phenotype — diffuse coronary burden — where valve replacement alone may be insufficient regardless of modality. Surgical revascularization at the time of SAVR addresses anatomic disease; whether it addresses the microvascular component that mean vFFR reflects is unanswered. Navitor's small-annulus performance narrows the hemodynamic gap that historically favored SAVR with root enlargement in this subgroup — but ESC 2025 still favors SAVR in patients <70 with low surgical risk, and no 12-month clinical composite from a single-arm registry changes that calculus.
Device & Technology
A 3D DenseNet121 deep-learning pipeline trained end-to-end on pre-TAVI whole-body CT (N=317, 5-fold CV, single-center, no external validation) achieved AUC 0.787 for identifying <12-month mortality — comparable to multimodal ML models requiring extensive clinical input. Sensitivity 85.3%, specificity 72.1%. STS-PROM and EuroSCORE II calibrate poorly in TAVI cohorts; image-based deep learning bypasses the feature-engineering bottleneck. Whether AUC 0.79 is actionable at the Heart Team table is the right question — not yet as a standalone tool, but as a nudge in borderline futility discussions, plausibly.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $88.25, down 1.15% on the day; +6.83% over six months
- Market cap $50.8B; trailing P/E 52.5, forward P/E 26.1; beta 0.85
- 52-week range $72.30 – $96.29
- Analyst target $100.96 (buy, 26 analysts)
- Next earnings Oct 29 (EPS est $0.74, revenue est $1.68B)
Edwards trades at a premium to the medtech complex on TAVR volume growth and the TriClip/PASCAL structural franchise. The October print will be the first opportunity to see whether ESC 2025's expanded TAVI indications (age ≥70 tricuspid AV) are pulling forward European volumes.
Medtronic (MDT)
- Close: $92.77, up 0.18%; +8.21% over six months
- Market cap $118.7B; trailing P/E 22.9, forward P/E 14.5; beta 0.57
- 52-week range $73.31 – $106.33
- Analyst target $104.83 (buy, 24 analysts)
- Next earnings Nov 17 (EPS est $1.33, revenue est $9.48B)
The Evolut FX platform's role in today's coronary embolization case is a case-level anecdote, not a franchise risk. The Navitor small-annulus data (Abbott's competitor to Evolut) may pressure Medtronic to publish more granular sub-annulus performance data of its own.
Abbott (ABT)
- Close: $102.23, down 0.13%; -4.50% over six months
- Market cap $178.1B; trailing P/E 33.1, forward P/E 16.9; beta 0.59
- 52-week range $81.97 – $137.49
- Analyst target $120.26 (buy, 25 analysts)
- Next earnings Oct 14 (EPS est $1.42, revenue est $12.99B)
Navitor's small-annulus performance is genuine competitive intelligence — the intra-annular self-expanding design was historically knocked for gradients in tight anatomy. A 1.1% rate of gradients ≥20 mmHg gives Abbott a talking point against balloon-expandable alternatives.
Boston Scientific (BSX)
- Close: $43.55, down 0.82%; -38.90% over six months
- Market cap $63.1B; trailing P/E 17.8, forward P/E 12.7; beta 0.57
- 52-week range $42.20 – $105.65
- Analyst target $62.00 (buy, 29 analysts)
- Next earnings Oct 28 (EPS est $0.78, revenue est $5.19B)
The six-month drawdown is a structural break, not a valve-specific story, but the ACURATE neo2 withdrawal earlier in the year removed BSX from the TAVR conversation. WATCHMAN and cardiac ablation now carry the structural narrative.
Anteris Technologies (AVR.AX)
- Close: A$11.81, up 1.11%; +41.44% over six months
- Market cap A$1.2B; forward P/E -5.45 (pre-revenue)
- 52-week range A$5.20 – A$15.47
- Analyst coverage limited (1 analyst, target A$13.00)
DurAVR continues to attract speculative capital on the single-piece bovine pericardial design thesis. Clinical readouts remain early-stage.
Market outlook: The four large caps are trading on macro medtech sentiment and non-valve franchises far more than on valve-specific catalysts. The vFFR finding, if it moves into practice, could expand pre-TAVI diagnostic spend without changing implant volumes — a modest tailwind for imaging and physiology vendors, neutral for valve manufacturers.
Clinical Trial Updates
Aortic:
- NCT07059728 — TAVR-Highflow II: High-flow nasal oxygenation vs standard nasal cannulae during TAVR sedation. Not yet recruiting. N=452. Sponsor: Hospital Clinic of Barcelona. Pragmatic peri-procedural comparison relevant to conscious-sedation TAVR programs.
Mitral & Tricuspid Valve-in-Valve:
- NCT07296016 — Asia-Pacific Mitral & Tricuspid ViV/ViR Registry: Recruiting. N=15 (early). Sponsor: Prince of Wales Hospital, Hong Kong. Registry-level data on ViV/ViR in a region historically underrepresented in structural heart trials.
No status changes today on landmark pivotal trials (EARLY TAVR follow-up, TRILUMINATE, TRISCEND II, RESHAPE-HF2, PRIMARY, REPAIR-MR). The next scheduled data drops of note remain TCT 2026 late-breakers and the EARLY TAVR extended follow-up.
Next up: Whether the vFFR-TAVI signal replicates in a prospective cohort will determine whether physiologic assessment enters the pre-TAVI workup — and whether the Heart Team's angiographic reflex needs a rewrite.